.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Eptifibatide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for eptifibatide?

Eptifibatide is the generic ingredient in two branded drugs marketed by Schering, Aurobindo Pharma Ltd, Teva Pharms Usa, and Amneal Pharms, and is included in five NDAs. There is one patent protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for eptifibatide. Five suppliers are listed for this compound.

Summary for Generic Name: eptifibatide

Tradenames:2
Patents:1
Applicants:4
NDAs:5
Drug Master File Entries: see list13
Suppliers / Packagers: see list5
Bulk Api Vendors: see list53
Clinical Trials: see list15
Patent Applications: see list5,321
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:eptifibatide at DailyMed

Pharmacology for Ingredient: eptifibatide

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998RXYesYes► Subscribe► Subscribe
Amneal Pharms
EPTIFIBATIDE
eptifibatide
INJECTABLE;INJECTION205581-002Dec 8, 2016RXNoNo► Subscribe► Subscribe
Teva Pharms Usa
EPTIFIBATIDE
eptifibatide
INJECTABLE;INJECTION091555-001Jun 5, 2015DISCNNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
EPTIFIBATIDE
eptifibatide
INJECTABLE;INJECTION206127-002Dec 8, 2015RXNoNo► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: eptifibatide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 19985,686,570► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 19985,968,902► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 19985,686,570► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 19985,807,825► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 19985,756,451► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc